Navigation Links
Vical to Present at UBS Global Life Sciences Conference
Date:9/15/2008

NEW YORK, Sept. 15 /PRNewswire-FirstCall/ -- The Vical Incorporated (Nasdaq: VICL) presentation at the UBS Global Life Sciences Conference on Monday, September 22, at 1 p.m. Eastern Daylight Time, will be available by live and archived webcast through the Events page at http://www.vical.com.

About Vical

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at http://www.vical.com.

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about the company's focus, collaborative partners, product candidates, and developmental status. Risks and uncertainties include whether any product candidates will be shown to be safe and efficacious in clinical trials, the timing of clinical trials, whether Vical or its collaborative partners will seek or gain approval to market any product candidates, the dependence of the company on its collaborative partners, and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

Contact: Alan R. Engbring

(858) 646-1127

Website: http://www.vical.com


'/>"/>
SOURCE Vical Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Society of Gynecologic Oncologists to Host Cervical Cancer Prevention Forum
2. Pioneer(R) Surgical Technology, Inc. Announces the Market Launch of the SlimFuse(TM) Anterior Cervical Plate System
3. Vical to Present at Upcoming Investor Conferences
4. Pioneer(R) Surgical Technology Announces First Human Implants of its NuNec(TM) Cervical Arthroplasty Device
5. Vical Announces News Release and Conference Call Schedule for First Quarter 2008 Financial Results
6. One4One Campaign to Raise $1 Million to Improve Cervical Cancer Education and Resources
7. Vical Licensee AnGes MG Files NDA in Japan for Collategene Angiogenesis Product
8. Vical to Present at Cowen and Company Health Care Conference
9. Vical to Present at BIO and BVGH Global Health Partnering Event
10. Survey Shows Most Women Cant Separate Fact From Fiction When It Comes to Cervical Cancer Prevention
11. Vical to Participate in Pandemic Influenza Panel at JPMorgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , Jan 19, 2017 Research and Markets ... has announced the addition of ... Material, Application - Forecast to 2025" report to their ... The report provides a detailed analysis on current and ... forecasts till 2025, using estimated market values as the base numbers ...
(Date:1/19/2017)... CALABASAS, Calif. , Jan. 19, 2017 /PRNewswire/ ... Mathias Schmidt , Ph.D., as chief executive ... board of directors. Dr. Schmidt brings to ArmaGen more ... on the research and development of biotherapeutics and ... biopharmaceutical executive with the diverse experience and skillset ...
(Date:1/19/2017)... NY (PRWEB) , ... January 19, 2017 , ... FireflySci ... an exponential rate. The tremendous growth is accounted to two main factors. ... table and the expanding network of vendors supplying FireflySci products all around the world. ...
(Date:1/19/2017)... -- Acupath Laboratories, Inc., a leading provider of sub-specialized ... Committee that will guide the company,s vision and strategy ... , a 15-year veteran of the anatomic pathology industry, ... Chief Sales Officer .  Prior to joining Acupath ... leadership roles at several leading lab industry organizations including, ...
Breaking Biology Technology:
(Date:1/11/2017)... DES MOINES, Iowa , Jan. 11, 2017 /PRNewswire/ ... another industry first with the release of its patent-pending ... to quickly and reliably perform calibrations, securely upload data ... more flexibility for the customer. "Fighting drunk ... not only for the public at large, but also ...
(Date:1/6/2017)... Jan. 6, 2017  Privately-held CalciMedica, Inc., announced ... healthy volunteers of a novel calcium release-activated calcium ... pancreatitis. Acute pancreatitis, sudden painful ... disorder, but can be very serious.  In severe cases ... where extended hospital stays, time in the ICU ...
(Date:1/6/2017)... -- Delta ID Inc., a leader in consumer-grade iris scanning ... CESĀ® 2017. Delta ID has collaborated with Gentex Corporation ... of iris scanning as a secure, reliable and convenient ... car, and as a way to elevate the security ... ID and Gentex will demonstrate (booth #7326 LVCC) a ...
Breaking Biology News(10 mins):